BPL1 postbiotic (Lactobacillus fermentate 500 mg daily) reduces visceral fat 15-20% and insulin resistance 15% by enhancing barrier function (reducing LPS 30%), promoting SCFA production (GPR43 signaling), and shifting microbiota toward butyrate-producers; effects persist post-supplementation.

Postbiotics (Lactobacillus fermentates) show superior stability and bioavailability (>90%) compared to probiotics (<1% survival); BPL1 reduces visceral fat 15-20%, improves insulin sensitivity +12%, and sustains effects post-supplementation via SCFA/bacteriocin signaling.

NMN/NR 250-500 mg daily restores muscle and tissue NAD+ by 10-30%, improves ATP production, enhances muscle insulin sensitivity (+20%), and activates sirtuins (NAD+-consuming deacetylases) implicated in longevity; safety excellent across 12-month trials.

Multi-MW hyaluronic acid (low MW for epidermal penetration + high MW for dermal gel matrix) combined with collagen peptides (10-15 g/day) stimulates fibroblast collagen synthesis; 12-week trials show +25% hydration, +22% elasticity, −30% wrinkle depth.

Silymarin (80-85% standardized extract) scavenges ROS, restores glutathione, and upregulates Phase II enzymes, reducing acetaminophen-induced injury by 30-50% and alcohol-induced liver fibrosis in 6-12 month trials; bioavailability enhanced by phytosomes or fat co-administration.

Piperine inhibits curcumin conjugation, increasing bioavailability 20-fold by blocking UGT/SULT enzymes; 5-20 mg piperine with 500-1,000 mg curcumin achieves clinical efficacy in joint pain and metabolic inflammation with no hepatic toxicity.